Michael Smith , Ph.D.
Michael Smith, Ph.D. is Application Manager for the Cell DIVE Multiplexed Imaging Solution at Leica Microsystems. He completed a Ph.D. in the genetics of DNA repair at Columbia University and a postdoctoral fellowship in genome integrity and cellular aging at Memorial Sloan Kettering Cancer Center, where he leveraged microscopy to understand the real-time dynamics of DNA homeostasis. His passion for answering biological questions using imaging technologies led him to his current position, where he provides technical expertise and customer support for the Cell DIVE platform.
IBEX, Cell DIVE, and RNA-Seq: A Multi-omics Approach to Follicular Lymphoma
In a recent study by Radtke et al., a multi-omics spatial biology approach helps shed light on early relapsing lymphoma patients
Spatial Biology: Learning the Landscape
Spatial Biology: Understanding the organization and interaction of molecules, cells, and tissues in their native spatial context
Complex Made Simple: Antibodies in Multiplexed Imaging
Build panels, plan studies, and get the most from precious reagents using this antibody multiplexing guide from Leica Microsystems
Multiplexed Imaging Types, Benefits and Applications
Multiplexed imaging is an emerging and exciting way to extract information from human tissue samples by visualizing many more biomarkers than traditional microscopy. By observing many biomarkers…
Multiplexed Imaging Glossary
Human tissues contain a many different biomarkers which can be explored to reveal the workings of biological pathways and interrogate disease states. Recent technological advances have made it…
Tumor MHC Expression and Intralesional IL2 Response in Melanoma
Genomics profiling and Cell DIVE multiplex imaging allows researchers to understand the immune cell phenotypes that most strongly predict response to IL2 immunotherapy in melanoma patients suffering…
Multiplex Imaging Reveals Survival Markers after Cancer Care
Colorectal cancer is a high incidence and high mortality cancer. Currently, postoperative chemotherapy benefits only a minority of patients, and thus, new tools are necessary to screen patients and…